Third-party umbilical cord blood-derived regulatory T cells prevent xenogenic graft-versus-host disease

Cytotherapy

Volumn 16, Issue 1, 2014, Pages 90-100

  Parmar, Simrit ^a   Liu, Xiaoying ^a   Tung, Shawndeep S ^a   Robinson, Simon N ^a   Rodriguez, Gabriel ^a   Cooper, Laurence J N ^a   Yang, Hui ^a   Shah, Nina ^a   Yang, Hong ^a   Konopleva, Marina ^a   Molldrem, Jeffery J ^a   Garcia Manero, Guillermo ^a   Najjar, Amer ^a   Yvon, Eric ^a   McNiece, Ian ^a   Rezvani, Katy ^a   Savoldo, Barbara ^b   Bollard, Catherine M ^b   Shpall, Elizabeth J ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

Cord blood; Graft vs. host disease; Regulatory T cells; Xenogenic GVHD model

Indexed keywords

CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR ALPHA; T LYMPHOCYTE RECEPTOR; T LYMPHOCYTE RECEPTOR V BETA; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL EXPANSION; CELL HOMING; CELL ISOLATION; CELL THERAPY; CELLULAR DISTRIBUTION; CONTROLLED STUDY; GRAFT VERSUS HOST REACTION; IN VITRO STUDY; IN VIVO STUDY; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; UMBILICAL CORD BLOOD;

CORD BLOOD; GRAFT VS. HOST DISEASE; REGULATORY T CELLS; XENOGENIC GVHD MODEL;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELL- AND TISSUE-BASED THERAPY; FETAL BLOOD; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MICE; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION, HOMOLOGOUS;

EID: 84891025751     PISSN: 14653249     EISSN: 14772566     Source Type: Journal    
DOI: 10.1016/j.jcyt.2013.07.009     Document Type: Article

References (35)

1. Sakaguchi S. Regulatory T cells: history and perspective. Methods Mol Biol 2011, 707:1-17.
2. Taylor P.A., Lees C.J., Blazar B.R. The infusion of ex vivo activated and expanded CD4(+)CD25(+) immune regulatory cells inhibits graft-versus-host disease lethality. Blood 2002, 99:3493-3499.
3. Edinger M., Hoffmann P., Ermann J., Drago K., Fathman C.G., Strober S., et al. CD4+CD25+ regulatory T cells preserve graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med 2003, 9:1144-1150.
4. Hippen K.L., Harker-Murray P., Porter S.B., Merkel S.C., Londer A., Taylor D.K., et al. Umbilical cord blood regulatory T-cell expansion and functional effects of tumor necrosis factor receptor family members OX40 and 4-1BB expressed on artificial antigen-presenting cells. Blood 2008, 112:2847-2857.
5. Di Ianni M., Falzetti F., Carotti A., Terenzi A., Castellino F., Bonifacio E., et al. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood 2011, 117:3921-3928.
6. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
7. King M.A., Covassin L., Brehm M.A., Racki W., Pearson T., Leif J., et al. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin Exp Immunol 2009, 157:104-118.
8. Chakraborty R., Mahendravada A., Perna S.K., Rooney C.M., Heslop H.E., Vera J.F., et al. Robust and cost effective expansion of human regulatory T cells highly functional in a xenograft model of graft-versus-host disease. Haematologica 2013, 98:533-537.
9. Parmar S., Robinson S.N., Komanduri K., St John L., Decker W., Xing D., et al. Ex vivo expanded umbilical cord blood T cells maintain naive phenotype and TCR diversity. Cytotherapy 2006, 8:149-157.
10. Arstila T.P., Casrouge A., Baron V., Even J., Kanellopoulos J., Kourilsky P. Adirect estimate of the human alphabeta T cell receptor diversity. Science 1999, 286:958-961.
11. Baron U., Floess S., Wieczorek G., Baumann K., Grutzkau A., Dong J., et al. DNA demethylation in the human FOXP3 locus discriminates regulatory T cells from activated FOXP3(+) conventional T cells. Eur J Immunol 2007, 37:2378-2389.
12. Sato T., Deiwick A., Raddatz G., Koyama K., Schlitt H.J. Interactions of allogeneic human mononuclear cells in the two-way mixed leucocyte culture (MLC): influence of cell numbers, subpopulations and cyclosporin. Clin Exp Immunol 1999, 115:301-308.
13. Adler H.S., Steinbrink K. MAP kinase p38 and its relation to T cell anergy and suppressor function of regulatory T cells. Cell Cycle 2008, 7:169-170.
14. Reddy V., Hill G.R., Pan L., Gerbitz A., Teshima T., Brinson Y., et al. G-CSF modulates cytokine profile of dendritic cells and decreases acute graft-versus-host disease through effects on the donor rather than the recipient. Transplantation 2000, 69:691-693.
15. Godfrey W.R., Spoden D.J., Ge Y.G., Baker S.R., Liu B., Levine B.L., et al. Cord blood CD4(+)CD25(+)-derived T regulatory cell lines express FoxP3 protein and manifest potent suppressor function. Blood 2005, 105:750-758.
16. Bettelli E., Carrier Y., Gao W., Korn T., Strom T.B., Oukka M., et al. Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 2006, 441:235-238.
17. Krenger W., Ferrara J.L. Graft-versus-host disease and the Th1/Th2 paradigm. Immunol Res 1996, 15:50-73.
18. Coghill J.M., Sarantopoulos S., Moran T.P., Murphy W.J., Blazar B.R., Serody J.S. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011, 117:3268-3276.
19. Aomatsu T., Imaeda H., Takahashi K., Fujimoto T., Kasumi E., Yoden A., et al. Tacrolimus (FK506) suppresses TNF-alpha-induced CCL2 (MCP-1) and CXCL10 (IP-10) expression via the inhibition of p38 MAP kinase activation in human colonic myofibroblasts. Int J Mol Med 2012, 30:1152-1158.
20. Wang J., Guan E., Roderiquez G., Norcross M.A. Inhibition of CCR5 expression by IL-12 through induction of beta-chemokines in human T lymphocytes. JImmunol 1999, 163:5763-5769.
21. Manicone A.M., Burkhart K.M., Lu B., Clark J.G. CXCR3 ligands contribute to Th1-induced inflammation but not to homing of Th1 cells into the lung. Exp Lung Res 2008, 34:391-407.
22. Choi S.W., Kitko C.L., Braun T., Paczesny S., Yanik G., Mineishi S., et al. Change in plasma tumor necrosis factor receptor 1 levels in the first week after myeloablative allogeneic transplantation correlates with severity and incidence of GVHD and survival. Blood 2008, 112:1539-1542.
23. Fontenot J.D., Gavin M.A., Rudensky A.Y. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat Immunol 2003, 4:330-336.
24. Sokol L., Cripe L., Kantarjian H., Sekeres M.A., Parmar S., Greenberg P., et al. Randomized, dose-escalation study of the p38alpha MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome. Leukemia 2013, 27:977-980.
25. van Rijn R.S., Simonetti E.R., Hagenbeek A., Hogenes M.C., de Weger R.A., Canninga-van Dijk M.R., et al. Anew xenograft model for graft-versus-host disease by intravenous transfer of human peripheral blood mononuclear cells in RAG2-/- gammac-/- double-mutant mice. Blood 2003, 102:2522-2531.
26. Ito R., Katano I., Kawai K., Hirata H., Ogura T., Kamisako T., et al. Highly sensitive model for xenogenic GVHD using severe immunodeficient NOG mice. Transplantation 2009, 87:1654-1658.
27. Verlinden S.F., Mulder A.H., de Leeuw J.P., van Bekkum D.W. Tlymphocytes determine the development of xeno GVHD and of human hemopoiesis in NOD/SCID mice following human umbilical cord blood transplantation. Stem Cells 1998, 16(Suppl 1):205-217.
28. Hippen KL, Merkel SC, Schirm DK, Nelson C, Tennis NC, Riley JL, etal. Generation and large-scale expansion of human inducible regulatory T cells that suppress graft-versus-host disease. Am J Transplant. 2011;11:1148-1157.
29. Cao T., Soto A., Zhou W., Wang W., Eck S., Walker M., et al. Ex vivo expanded human CD4+CD25+Foxp3+ regulatory T cells prevent lethal xenogenic graft versus host disease (GVHD). Cell Immunol 2009, 258:65-71.
30. Gregoire-Gauthier J., Selleri S., Fontaine F., Dieng M.M., Patey N., Despars G., et al. Therapeutic efficacy of cord blood-derived mesenchymal stromal cells for the prevention of acute GVHD in a xenogenic mouse model. Stem Cells Dev 2012, 21:1616-1626.
31. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25): breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. JImmunol 1995, 155:1151-1164.
32. Hoffmann P., Ermann J., Edinger M., Fathman C.G., Strober S. Donor-type CD4(+)CD25(+) regulatory T cells suppress lethal acute graft-versus-host disease after allogeneic bone marrow transplantation. JExp Med 2002, 196:389-399.
33. Duarte J.H., Zelenay S., Bergman M.L., Martins A.C., Demengeot J. Natural Treg cells spontaneously differentiate into pathogenic helper cells in lymphopenic conditions. Eur J Immunol 2009, 39:948-955.
34. Brunstein C.G., Miller J.S., Cao Q., McKenna D.H., Hippen K.L., Curtsinger J., et al. Infusion of ex vivo expanded T regulatory cells in adults transplanted with umbilical cord blood: safety profile and detection kinetics. Blood 2011, 117:1061-1070.
35. Veerapathran A., Pidala J., Beato F., Yu X.Z., Anasetti C. Ex vivo expansion of human Tregs specific for alloantigens presented directly or indirectly. Blood 2011, 118:5671-5680.